Clinical and immunological significance of HLA-E in stem cell transplantation and cancer

Tissue Antigens

Volumn 84, Issue 6, 2014, Pages 523-535

  Wieten, L ^a   Mahaweni, N M ^a   Voorter, C E M ^a   Bos, G M J ^a   Tilanus, M G J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presentation; Cancer; Human leukocyte antigen E; Immune response; NK Natural killer cell; Stem cell transplantation; T cell

Indexed keywords

HLA ANTIGEN CLASS 1; HLA-E ANTIGEN; KLRC2 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; GENETIC POLYMORPHISM; GENETICS; HUMAN; IMMUNOLOGY; NEOPLASM; STEM CELL TRANSPLANTATION;

CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; POLYMORPHISM, GENETIC; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; STEM CELL TRANSPLANTATION;

EID: 84911415636     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12478     Document Type: Review

References (80)

1. Sullivan LC, Hoare HL, McCluskey J, Rossjohn J, Brooks AG. A structural perspective on MHC class Ib molecules in adaptive immunity. Trends Immunol 2006: 27: 413-20.
2. van Hall T, Oliveira CC, Joosten SA, Ottenhoff TH. The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect 2010: 12: 910-8.
3. Sullivan LC, Clements CS, Rossjohn J, Brooks AG. The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity. Tissue Antigens 2008: 72: 415-24.
4. O'Callaghan CA, Tormo J, Willcox BE et al. Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol Cell 1998: 1: 531-41.
5. Martoglio B, Dobberstein B. Signal sequences: more than just greasy peptides. Trends Cell Biol 1998: 8: 410-5.
6. Michaelsson J, Teixeira de Matos C, Achour A, Lanier LL, Karre K, Soderstrom K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 2002: 196: 1403-14.
7. Iwaszko M, Bogunia-Kubik K. Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch Immunol Ther Exp (Warsz) 2011: 59: 353-67.
8. Strong RK, Holmes MA, Li P, Braun L, Lee N, Geraghty DE. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem 2003: 278: 5082-90.
9. Tomasec P, Braud VM, Rickards C et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000: 287: 1031.
10. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004: 53: 904-10.
11. Lampen MH, Hassan C, Sluijter M et al. Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol Immunol 2013: 53: 126-31.
12. Nachmani D, Zimmermann A, Oiknine Djian E et al. MicroRNA editing facilitates immune elimination of HCMV infected cells. PLoS Pathog 2014: 10: e1003963.
13. Castelli EC, Veiga-Castelli LC, Yaghi L, Moreau P. Transcriptional and posttranscriptional regulations of the HLA-G gene. Journal of Immunological Research 2014: 2014: 734068.
14. Kulkarni S, Savan R, Qi Y et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011: 472: 495-8.
15. Braud VM, Allan DS, O'Callaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998: 391: 795-9.
16. Wada H, Matsumoto N, Maenaka K, Suzuki K, Yamamoto K. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues. Eur J Immunol 2004: 34: 81-90.
17. Kaiser BK, Barahmand-Pour F, Paulsene W, Medley S, Geraghty DE, Strong RK. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol 2005: 174: 2878-84.
18. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J 1999: 18: 4250-60.
19. Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013: 13: 133-44.
20. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009: 9: 568-80.
21. Llano M, Lee N, Navarro F et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998: 28: 2854-63.
22. Cheent KS, Jamil KM, Cassidy S et al. Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94. Proc Natl Acad Sci U S A 2013: 110: 16981-6.
23. Cassidy SA, Cheent KS, Khakoo SI. Effects of peptide on NK cell-mediated MHC I recognition. Front Immunol 2014: 5: 133.
24. Jabri B, Selby JM, Negulescu H et al. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity 2002: 17: 487-99.
25. Moser JM, Gibbs J, Jensen PE, Lukacher AE. CD94-NKG2A receptors regulate antiviral CD8(+) T cell responses. Nat Immunol 2002: 3: 189-95.
26. Guma M, Budt M, Saez A et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 2006: 107: 3624-31.
27. Garcia P, Llano M, de Heredia AB et al. Human T cell receptor-mediated recognition of HLA-E. Eur J Immunol 2002: 32: 936-44.
28. Pietra G, Romagnani C, Manzini C, Moretta L, Mingari MC. The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol 2010: 2010: 907092.
29. Pietra G, Romagnani C, Mazzarino P et al. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A 2003: 100: 10896-901.
30. Salerno-Goncalves R, Fernandez-Vina M, Lewinsohn DM, Sztein MB. Identification of a human HLA-E-restricted CD8+ T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 2004: 173: 5852-62.
31. Heinzel AS, Grotzke JE, Lines RA et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. J Exp Med 2002: 196: 1473-81.
32. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 2004: 5: 516-23.
33. Jiang H, Canfield SM, Gallagher MP et al. HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest 2010: 120: 3641-50.
34. Liu XX, Pan FH, Tian W. Characterization of HLA-E polymorphism in four distinct populations in Mainland China. Tissue Antigens 2012: 80: 26-35.
35. Grimsley C, Kawasaki A, Gassner C et al. Definitive high resolution typing of HLA-E allelic polymorphisms: identifying potential errors in existing allele data. Tissue Antigens 2002: 60: 206-12.
36. Arnaiz-Villena A, Vargas-Alarcon G, Serrano-Vela JI et al. HLA-E polymorphism in Amerindians from Mexico (Mazatecans), Colombia (Wayu) and Chile (Mapuches): evolution of MHC-E gene. Tissue Antigens 2007: 69 (Suppl 1): 132-5.
37. Grimsley C, Ober C. Population genetic studies of HLA-E: evidence for selection. Hum Immunol 1997: 52: 33-40.
38. Matte C, Lacaille J, Zijenah L, Ward B, Roger M. HLA-G and HLA-E polymorphisms in an indigenous African population. The ZVITAMBO Study Group. Hum Immunol 2000: 61: 1150-6.
39. Felicio LP, Porto IO, Mendes-Junior CT et al. Worldwide HLA-E nucleotide and haplotype variability reveals a conserved gene for coding and 3' untranslated regions. Tissue Antigens 2014: 83: 82-93.
40. Pacasova R, Martinozzi S, Boulouis HJ et al. Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice. J Immunol 1999: 162: 5190-6.
41. Romagnani C, Pietra G, Falco M et al. Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proc Natl Acad Sci U S A 2002: 99: 11328-33.
42. Tamouza R, Rocha V, Busson M et al. Association of HLA-E polymorphism with severe bacterial infection and early transplant-related mortality in matched unrelated bone marrow transplantation. Transplantation 2005: 80: 140-4.
43. Tamouza R, Busson M, Rocha V et al. Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation. Transplantation 2006: 82: 1436-40.
44. Danzer M, Polin H, Proll J et al. Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation. Transplantation 2009: 88: 528-32.
45. Ludajic K, Rosenmayr A, Fae I et al. Association of HLA-E polymorphism with the outcome of hematopoietic stem-cell transplantation with unrelated donors. Transplantation 2009: 88: 1227-8.
46. Hosseini E, Schwarer AP, Ghasemzadeh M. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation. Iran J Allergy Asthma Immunol 2012: 11: 15-21.
47. Hosseini E, Schwarer AP, Jalali A, Ghasemzadeh M. The impact of HLA-E polymorphisms on relapse following allogeneic hematopoietic stem cell transplantation. Leuk Res 2013: 37: 516-9.
48. Furst D, Bindja J, Arnold R et al. HLA-E polymorphisms in hematopoietic stem cell transplantation. Tissue Antigens 2012: 79: 287-90.
49. Foley B, Cooley S, Verneris MR et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012: 119: 2665-74.
50. Al-Lamki RS, Bradley JR, Pober JS. Endothelial cells in allograft rejection. Transplantation 2008: 86: 1340-8.
51. Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou JP, Charreau B. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2007: 109: 2806-14.
52. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011: 331: 1565-70.
53. del Campo AB, Carretero J, Aptsiauri N, Garrido F. Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 2012: 79: 147-54.
54. Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, Pistillo MP. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol 2005: 66: 1-12.
55. Derre L, Corvaisier M, Charreau B et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 2006: 177: 3100-7.
56. de Kruijf EM, Sajet A, van Nes JG et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010: 185: 7452-9.
57. Hirankarn N, Kimkong I, Mutirangura A. HLA-E polymorphism in patients with nasopharyngeal carcinoma. Tissue Antigens 2004: 64: 588-92.
58. Hassen E, Ghedira R, Ghandri N et al. Lack of association between human leukocyte antigen-E alleles and nasopharyngeal carcinoma in Tunisians. DNA Cell Biol 2011: 30: 603-9.
59. Moya-Quiles MR, Martinez-Escribano J, Guerra-Perez N et al. Lack of association between HLA-E polymorphism and primary cutaneous melanoma in Spanish patients. J Dermatol Sci 2005: 40: 62-4.
60. Zhen ZJ, Ling JY, Cai Y, Luo WB, He YJ. Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. Med Oncol 2013: 30: 482.
61. Bossard C, Bezieau S, Matysiak-Budnik T et al. HLA-E/beta2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer 2012: 131: 855-63.
62. Gooden M, Lampen M, Jordanova ES et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci U S A 2011: 108: 10656-61.
63. Bertone S, Schiavetti F, Bellomo R et al. Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol 1999: 29: 23-9.
64. Campoli M, Ferrone S. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 2008: 72: 321-34.
65. Allard M, Oger R, Vignard V et al. Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One 2011: 6: e21118.
66. Morandi F, Cangemi G, Barco S et al. Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patients. Biomed Res Int 2013: 2013: 956878.
67. Levy EM, Sycz G, Arriaga JM et al. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun 2009: 15: 91-100.
68. Berman HM, Westbrook J, Feng Z et al. The protein data bank. Nucleic Acids Res 2000: 28: 235-42.
69. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006: 22: 195-201.
70. Biasini M, Bienert S, Waterhouse A et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 2014: 42: W252-8.
71. Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, Schwede T. Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc 2009: 4: 1-13.
72. Guex N, Peitsch MC, Schwede T. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis 2009: 30 (Suppl 1): S162-73.
73. Kren L, Slaby O, Muckova K et al. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance? Neuropathology 2011: 31: 129-34.
74. Mittelbronn M, Simon P, Loffler C et al. Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J Neuroimmunol 2007: 189: 50-8.
75. Benevolo M, Mottolese M, Tremante E et al. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med 2011: 9: 184.
76. Kren L, Fabian P, Slaby O et al. Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications. Pathol Res Pract 2012: 208: 45-9.
77. Zeestraten EC, Reimers MS, Saadatmand S et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer 2014: 110: 459-68.
78. Nguyen S, Dhedin N, Vernant JP et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005: 105: 4135-42.
79. Gross C, Holler E, Stangl S et al. An Hsp70 peptide initiates NK cell killing of leukemic blasts after stem cell transplantation. Leuk Res 2008: 32: 527-34.
80. Veiga-Castelli LC, de Paula Cruz AS, Inacio MM et al. Lack of association between HLA-E polymorphisms and transitional cell carcinoma of the bladder. Tissue Antigens 2013: 82: 197-200.